LLY Jun 2024 310.000 call
- Yahoo Finance Video
Eli Lilly stock jumps on weight-loss drug sales forecast
Shares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year revenue increase in a figure of $8.77 billion. Ultimately, this revenue print fell short of estimates ($8.92 billion). The pharmaceutical giant did, however, raise its annual sales forecast by $2 billion due to an insatiable demand for its GLP-1 weight-loss drugs Mounjaro and Zepbound. Yahoo Finance Health Reporter Anjalee Khemlani joins Catalysts to break down the report and what it means for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino
- Yahoo Finance
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
- Reuters
US STOCKS-Wall St falls on hot labor costs data, caution before Fed verdict
Wall Street's main indexes fell on Tuesday with caution prevailing ahead of the Federal Reserve's interest-rate decision and as stronger-than-expected labor costs hinted at persistent inflation. U.S. labor costs increased in the first quarter amid a rise in wages and benefits, confirming the surge in inflation early in the year that will likely delay a much-anticipated interest rate cut later in 2024. The data comes ahead of the Federal Reserve Open Market Committee's (FOMC) two-day meeting during the day, with the interest rate verdict and Chair Jerome Powell's remarks at the end of the event in focus.
